AngioDynamics sells medical devices for treating cardiovascular disease and cancer. The company organizes its business into the Med Tech and Med Device segments. The Med Tech segment features higher-growth technology platforms, including the Auryon laser atherectomy system for peripheral arterial disease and the AngioVac and AlphaVac mechanical thrombectomy devices for blood clot removal. It also includes NanoKnife, an irreversible electroporation system used to treat soft tissue tumors, which the company is positioning as a focal therapy for prostate cancer following expanded FDA clearance and new reimbursement codes. The Med Device segment consists of a mature portfolio of interventional consumables like catheters, guidewires, and ports that generate steady cash flow. AngioDynamics employs a capital-plus-disposable business model in Med Tech, where it sells equipment and generates recurring revenue from single-use components, while the Med Device business relies on high-volume consumable sales. The company's strategy focuses on shifting its revenue mix toward the higher-margin Med Tech segment and expanding its clinical data to support new applications for its core technologies. To improve operating efficiency, AngioDynamics is transitioning its manufacturing to Costa Rica and expanding its international presence in Europe.